Author(s):
Mukund M. Pache, Rutuja R. Pangavhane, Mayuri N. Jagtap, Avinash B. Darekar
Email(s):
mukundpache918@gmail.com
DOI:
10.52711/2231-5659.2025.00009 
Address:
Mukund M. Pache1, Rutuja R. Pangavhane2, Mayuri N. Jagtap3, Avinash B. Darekar4
1,2Department of Pharmacy, K.V.N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education and Research, Nashik, 422002, Maharashtra, India.
3Head, Department of Pharmacology, K.V.N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education and Research, Nashik, 422002, Maharashtra, India.
4Principal, K.V.N. Naik S. P. Sanstha's, Institute of Pharmaceutical Education and Research, Nashik, 422002, Maharashtra, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 1,
Year - 2025
ABSTRACT:
AI is notably overcoming the long-standing problems, such as high costs, prolonged timelines, and complex biological data analysis, in drug discovery, which in turn is revolutionising the pharmaceutical industry. This article is aimed at making readers realise the significance of AI in drug discovery and what actual changes it has triggered by innovating in areas of target identification, virtual screening, automated drug design, compound optimisation, and biomarker discovery. AI applications, like deep learning or generative models, are now moving much faster and are more accurate in the identification of potential drug targets, while AI-powered virtual screening is the advanced method that makes possible lead identification by the prediction of ligand-receptor binding affinities. For automated drug design tools, generative adversarial networks (GANs) are used for optimising the properties of new molecules, thereby producing the most effective drugs, and reinforcement learning allows the reduction of the possible side effects to further improve the quality of compounds. Biomarker discovery, which is powered by AI, helps in precision medicine by allowing patient stratification and optimisation of clinical trials. Nevertheless, the difficulties in this matter are still poignant. Data handling, transparency in models, regulation uncertainties, and ethical problems such as privacy and bias limit AI in drug development. Collaboration of data sharing among the organisations and the progress in the regulatory frameworks are the most important points to be addressed to solve these issues. Despite these drawbacks, the future of artificial intelligence applications is quite bright, showing possibilities to decrease the spending on R&D, cut the timelines for drug development, deliver precision medicines that improve patients' outcomes, and spur the world's global healthcare solutions.
Cite this article:
Mukund M. Pache, Rutuja R. Pangavhane, Mayuri N. Jagtap, Avinash B. Darekar. The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(1):61-7. doi: 10.52711/2231-5659.2025.00009
Cite(Electronic):
Mukund M. Pache, Rutuja R. Pangavhane, Mayuri N. Jagtap, Avinash B. Darekar. The AI-Driven Future of Drug Discovery: Innovations, Applications, and Challenges. Asian Journal of Research in Pharmaceutical Sciences. 2025; 15(1):61-7. doi: 10.52711/2231-5659.2025.00009 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2025-15-1-9
REFERENCES:
1. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, et al. How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nat Rev Drug Discov. 2010 Mar; 9(3): 203–14.
2. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: new estimates of R&D costs. Journal of Health Economics. 2016 May; 47:20–33.
3. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018 Feb;17(2): 97–113.
4. Mak KK, Pichika MR. Artificial intelligence in drug development: present status and future prospects. Drug Discovery Today. 2019 Mar;24(3):773–80.
5. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019 Apr 1; 20(2): 273–86.
6. Chen H, Engkvist O, Wang Y, Olivecrona M, Blaschke T. The rise of deep learning in drug discovery. Drug Discovery Today. 2018 Jun; 23(6): 1241–50.
7. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with Alpha Fold. Nature. 2021 Aug 26; 596(7873): 583–9.
8. Wang X, Liu J, Zhang C, Wang S. SSGraphCPI: A novel model for predicting compound-protein interactions based on deep learning. International Journal of Molecular Sciences. 2022; 23(7): 3780.
9. Gomes J, Ramsundar B, Feinberg EN, Pande VS. Atomic convolutional networks for predicting protein-ligand binding affinity. arXiv preprint arXiv:1703.10603. 2017 Mar 30.
10. Mamoshina P, Vieira A, Putin E, Zhavoronkov A. Applications of Deep Learning in Biomedicine. Mol Pharmaceutics. 2016 May 2; 13(5): 1445–54.
11. Gawehn E, Hiss JA, Schneider G. Deep Learning in Drug Discovery. Molecular Informatics. 2016 Jan; 35(1): 3–14.
12. Yang X, Wang Y, Byrne R, Schneider G, Yang S. Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery. Chem Rev. 2019 Sep 25; 119(18): 10520–94.
13. Goodfellow I, Pouget-Abadie J, Mirza M, Xu B, Warde-Farley D, Ozair S, et al. Generative adversarial networks. Commun ACM. 2020 Oct 22; 63(11): 139–44.
14. Zhavoronkov A, Ivanenkov YA, Aliper A, Veselov MS, Aladinskiy VA, Aladinskaya AV, et al. Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nat Biotechnol. 2019 Sep; 37(9): 1038–40.
15. Popova M, Isayev O, Tropsha A. Deep reinforcement learning for de novo drug design. Sci Adv. 2018 Jul 6; 4(7): EAAP7885.
16. Stokes JM, Yang K, Swanson K, Jin W, Cubillos-Ruiz A, Donghia NM, et al. A Deep Learning Approach to Antibiotic Discovery. Cell. 2020 Feb; 180(4): 688-702.e13.
17. Segler MHS, Kogej T, Tyrchan C, Waller MP. Generating Focused Molecule Libraries for Drug Discovery with Recurrent Neural Networks. ACS Cent Sci. 2018 Jan 24; 4(1): 120–31.
18. Sanchez-Lengeling B, Aspuru-Guzik A. Inverse molecular design using machine learning: Generative models for matter engineering. Science. 2018 Jul 27; 361(6400): 360–5.
19. Topol EJ. High-performance medicine: the convergence of human and artificial intelligence. Nat Med. 2019 Jan;25(1):44–56.
20. Ghaffari Laleh N, Ligero M, Perez-Lopez R, Kather JN. Facts and hopes on the use of artificial intelligence for predictive immunotherapy biomarkers in cancer. Clinical Cancer Research. 2023; 29(2): 316–23.
21. Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Pizzi AD, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Annals of Oncology. 2019; 30(6): 998–1004.
22. Park S, Ahn CH, Jung G, Lee S, Paeng K, Shin J, et al. Deep learning-based predictive biomarker for immune checkpoint inhibitor response in metastatic non-small cell lung cancer. JCO. 2019 May 20; 37(15_suppl): 9094–9094.
23. Xie J, Luo X, Deng X, Tang Y, Tian W, Cheng H, et al. Advances in artificial intelligence to predict cancer immunotherapy efficacy. Frontiers in Immunology. 2023; 13: 1076883.
24. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019 Jun; 18(6): 463–77.
25. Lo YC, Rensi SE, Torng W, Altman RB. Machine learning in chemoinformatics and drug discovery. Drug Discovery Today. 2018 Aug; 23(8): 1538–46.
26. Korotcov A, Tkachenko V, Russo DP, Ekins S. Comparison of Deep Learning with Multiple Machine Learning Methods and Metrics Using Diverse Drug Discovery Data Sets. Mol Pharmaceutics. 2017 Dec 4; 14(12): 4462–75.
27. Rajkomar A, Dean J, Kohane I. Machine Learning in Medicine. N Engl J Med. 2019 Apr 4; 380(14): 1347–58.
28. Smalley E. AI-powered drug discovery captures pharma interest. Nature Biotechnology. 2017; 35(7):604–6.
29. Gao B, Qiang B, Tan H, Jia Y, Ren M, Lu M, Liu J, Ma WY, Lan Y. Drugclip: Contrasive protein-molecule representation learning for virtual screening. Advances in Neural Information Processing Systems. 2024 Feb 13; 36.
30. Esteva A, Robicquet A, Ramsundar B, Kuleshov V, DePristo M, Chou K, et al. A guide to deep learning in healthcare. Nat Med. 2019 Jan; 25(1):24–9.
31. Harrer S, Shah P, Antony B, Hu J. Artificial intelligence for clinical trial design. Trends in Pharmacological Sciences. 2019; 40(8): 577–91.
32. Miyasato G, Kasivajjala VC, Misra M, Kumar K, Kadam AS, Friedman HS. AI-driven real-time patient identification for randomized controlled trials. JCO. 2023 Jun 1;41(16_suppl):e13565–e13565.
33. Bhande P. Adoption of AI-Enabled Solutions for Patient Recruitment Process in Clinical Trials.
34. Chopra H, Shin DK, Munjal K, Dhama K, Emran TB. Revolutionizing clinical trials: the role of AI in accelerating medical breakthroughs. International Journal of Surgery. 2023; 109(12): 4211–20.
35. Richardson P, Griffin I, Tucker C, Smith D, Oechsle O, Phelan A, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. The Lancet. 2020 Feb; 395(10223): e30–1.
36. Krittanawong C, Zhang H, Wang Z, Aydar M, Kitai T. Artificial Intelligence in Precision Cardiovascular Medicine. Journal of the American College of Cardiology. 2017 May; 69(21):2657–64.
37. Richardson PJ, Robinson BW, Smith DP, Stebbing J. The AI-assisted identification and clinical efficacy of baricitinib in the treatment of COVID-19. Vaccines. 2022; 10(6):951.
38. Smith DP, Oechsle O, Rawling MJ, Savory E, Lacoste AM, Richardson PJ. Expert-augmented computational drug repurposing identified baricitinib as a treatment for COVID-19. Frontiers in Pharmacology. 2021; 12:709856.
39. Stebbing J, Krishnan V, De Bono S, Ottaviani S, Casalini G, Richardson PJ, et al. Mechanism of baricitinib supports artificial intelligence‐predicted testing in COVID ‐19 patients. EMBO Mol Med. 2020 Aug 7; 12(8): e12697.
40. Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health. 2020; 2(12): e667–76.
41. Dilsizian SE, Siegel EL. Artificial Intelligence in Medicine and Cardiac Imaging: Harnessing Big Data and Advanced Computing to Provide Personalized Medical Diagnosis and Treatment. Curr Cardiol Rep. 2014 Jan; 16(1): 441.
42. Bejnordi BE, Veta M, Van Diest PJ, Van Ginneken B, Karssemeijer N, Litjens G, Van Der Laak JA, Hermsen M, Manson QF, Balkenhol M, Geessink O. Diagnostic assessment of deep learning algorithms for detection of lymph node metastases in women with breast cancer. JAMA. 2017 Dec 12; 318(22): 2199-210.
43. Gandomi A, Haider M. Beyond the hype: big data concepts, methods, and analytics. International Journal of Information Management. 2015;35(2):137–44.
44. Patel NM, Michelini VV, Snell JM, Balu S, Hoyle AP, Parker JS, et al. Enhancing next-generation sequencing-guided cancer care through cognitive computing. The oncologist. 2018;23(2):179–85.
45. Esteva A, Chou K, Yeung S, Naik N, Madani A, Mottaghi A, et al. Deep learning-enabled medical computer vision. NPJ Digital Medicine. 2021;4(1):5.
46. Beaubier N, Bontrager M, Huether R, Igartua C, Lau D, Tell R, et al. Integrated genomic profiling expands clinical options for patients with cancer. Nature biotechnology. 2019;37(11):1351–60.
47. André F, Ciccolini J, Spano JP, Penault-Llorca F, Mounier N, Freyer G, et al. Personalized Medicine in Oncology: Where Have we Come from and where are we Going? Pharmacogenomics. 2013 Jun;14(8):931–9.
48. Kalia M. Personalized oncology: Recent advances and future challenges. Metabolism. 2013;62: S11–4.
49. Lee SI, Celik S, Logsdon BA, Lundberg SM, Martins TJ, Oehler VG, et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nature Communications. 2018; 9(1): 42.
50. He J, Baxter SL, Xu J, Xu J, Zhou X, Zhang K. The practical implementation of artificial intelligence technologies in medicine. Nature Medicine. 2019; 25(1): 30–6.
51. Miotto R, Wang F, Wang S, Jiang X, Dudley JT. Deep learning for healthcare: review, opportunities and challenges. Briefings in Bioinformatics. 2018; 19(6): 1236–46.
52. Blanco-Gonzalez A, Cabezon A, Seco-Gonzalez A, Conde-Torres D, Antelo-Riveiro P, Pineiro A, et al. The role of AI in drug discovery: challenges, opportunities, and strategies. Pharmaceuticals. 2023; 16(6): 891.
53. Tiwari PC, Pal R, Chaudhary MJ, Nath R. Artificial intelligence revolutionizing drug development: Exploring opportunities and challenges. Drug Development Research. 2023 Dec; 84(8): 1652–63.
54. Walters WP, Barzilay R. Critical assessment of AI in drug discovery. Expert Opinion on Drug Discovery. 2021 Sep 2; 16(9): 937–47.
55. Kumar SA, Ananda Kumar TD, Beeraka NM, Pujar GV, Singh M, Narayana Akshatha HS, et al. Machine Learning and Deep Learning in Data-Driven Decision Making of Drug Discovery and Challenges in High-Quality Data Acquisition in the Pharmaceutical Industry. Future Med Chem. 2022 Feb; 14(4): 245–70.
56. Doshi-Velez F, Kim B. Towards a rigorous science of interpretable machine learning. arXiv preprint arXiv:1702.08608. 2017 Feb 28.
57. Holzinger A, Langs G, Denk H, Zatloukal K, Müller H. Causability and explainability of artificial intelligence in medicine. WIREs Data Min and Knowl. 2019 Jul; 9(4): e1312.
58. Samek W. Explainable artificial intelligence: Understanding, visualizing and interpreting deep learning models. arXiv preprint arXiv:170808296. 2017;
59. Luxton DD. Recommendations for the ethical use and design of artificial intelligent care providers. Artificial Intelligence in Medicine. 2014; 62(1):1–10.
60. Gerke S, Minssen T, Cohen G. Ethical and legal challenges of artificial intelligence-driven healthcare. In Artificial Intelligence in Healthcare. 2020 Jan 1 (pp. 295-336). Academic Press.
61. Amann J, Blasimme A, Vayena E, Frey D, Madai VI, Precise4Q Consortium. Explainability for artificial intelligence in healthcare: a multidisciplinary perspective. BMC Medical Informatics and Decision Making. 2020 Dec; 20:1-9.
62. Wiens J, Saria S, Sendak M, Ghassemi M, Liu VX, Doshi-Velez F, et al. Do no harm: a roadmap for responsible machine learning for health care. Nat Med. 2019 Sep;25(9):1337–40.
63. Mehrabi N, Morstatter F, Saxena N, Lerman K, Galstyan A. A Survey on Bias and Fairness in Machine Learning. ACM Comput Surv. 2022 Jul 31;54(6):1–35.
64. Patel VL, Shortliffe EH, Stefanelli M, Szolovits P, Berthold MR, Bellazzi R, et al. The coming of age of artificial intelligence in medicine. Artificial Intelligence in Medicine. 2009;46(1):5–17.
65. Yu KH, Beam AL, Kohane IS. Artificial intelligence in healthcare. Nature Biomedical Engineering. 2018; 2(10):719–31.
66. Davenport T, Kalakota R. The potential for artificial intelligence in healthcare. Future healthcare journal. 2019; 6(2): 94–8.
67. Ribeiro MT, Singh S, Guestrin C. " Why should i trust you?” Explaining the predictions of any classifier. InProceedings of the 22nd ACM SIGKDD international conference on knowledge discovery and data mining 2016 Aug 13 (pp. 1135-1144).
68. Sheller MJ, Edwards B, Reina GA, Martin J, Pati S, Kotrotsou A, et al. Federated learning in medicine: facilitating multi-institutional collaborations without sharing patient data. Scientific Reports. 2020; 10(1): 12598.
69. Munoz-Price LS, Poirel L, Bonomo RA, Schwaber MJ, Daikos GL, Cormican M, et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases. 2013 Sep; 13(9): 785–96.
70. Srivastava R. Quantum computing in drug discovery. Information System and Smart City. 2023 Dec 11; 3(1).
71. Ravichandran M, Maddalo D. Applications of CRISPR-Cas9 for advancing precision medicine in oncology: from target discovery to disease modeling. Frontiers in Genetics. 2023; 14: 1273994.
72. Flöther FF. The state of quantum computing applications in health and medicine. Research Directions: Quantum Technologies. 2023; 1: e10.